Treosulfan monitoring in pediatric stem cell transplant
Part of Blood & lymphatic, Cancer clinical trials.
This study watches how the chemotherapy drug Treosulfan works in children getting a stem cell transplant. The goal is to make sure the dose is just right for each child.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 0 and 18 years old.
- You must be scheduled for a stem cell transplant that uses Treosulfan as part of the conditioning therapy.
- You must not have a serious active infection, severe heart, liver, or kidney problems.
- If you are a female and able to become pregnant, you need a negative pregnancy test before starting.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a chemotherapy drug called treosulfan as part of the preparation for a stem cell transplant (a type of treatment that replaces your bone marrow) in people with Nijmegen breakage syndrome. The goal is to see if this approach is safe and works well.
This trial tests whether the chemotherapy medicine treosulfan (Trecondi® Ideogen) works well and is safe for people with myeloma who are moving on to high-dose chemotherapy plus their own stem cell transplant. It may help strengthen the transplant “conditioning” treatment before the transplant.
This trial tests a low-dose chemotherapy regimen (treosulfan) combined with a drug called PTCy to prepare children with Nijmegen Breakage Syndrome for a stem cell transplant. The goal is to reduce side effects while helping the donor cells take hold safely.
This trial compares two chemotherapy drugs, treosulfan and melphalan, used before a stem cell transplant in people with AML or MDS. The goal is to see which one works better with a special anti-rejection drug called PTCy.
This Phase 2 study tests a specific chemotherapy combination (treosulfan, fludarabine, and thiotepa) before an unrelated or matched donor stem cell transplant. It may help people with certain non-cancer blood and immune disorders by trying to reset the immune system using donor stem cells.
This trial tests a combination of four medicines (cyclophosphamide, abatacept, vedolizumab, and ruxolitinib) to prevent graft-versus-host disease (GVHD) after a stem cell transplant for children and young adults with certain blood cancers. The goal is to see if this approach reduces the risk of GVHD, a serious complication where donor cells attack the body.
Hear when a new Non-malignant Disorders trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.